The endocannabinoid system as a target for the treatment of neuronal damage

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 4, 2010, Pages 387-404

  Fernández Ruiz, Javier ^a   García, Concepción ^a   Sagredo, Onintza ^a   Gómez Ruiz, María ^a   De Lago, Eva ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannabinoid signaling system; Cannabinoids; CB1 and CB2 receptors; Neurodegeneration; Neuroprotection; Neuroregeneration

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AJULEMIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOL; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DIZOCILPINE; DRONABINOL; ENDOCANNABINOID; GLUTAMIC ACID; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; PALMITYLSULFONYL FLUORIDE; PHENCYCLIDINE; RIMONABANT; UNINDEXED DRUG;

ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CALCIUM TRANSPORT; CELL DEATH; CELL SURVIVAL; CHRONIC DISEASE; GLIA; HUMAN; NAUSEA; NERVE INJURY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; REVIEW; VASCULARIZATION; VOMITING;

ANIMALS; CELL DEATH; CELL SURVIVAL; ENDOCANNABINOIDS; HUMANS; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 77949564177     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728221003709792     Document Type: Review

References (128)

1. Howlett AC, Bidaut-Russell M, Devane WA, et al. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990;13:420-423
2. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564
3. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949
4. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008;13:147-159
5. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65
6. Fernández-Ruiz J, Romero J, Velasco G, et al. Cannabinoid CB2 receptor: a new target for the control of neural cell survival? Trends Pharmacol Sci 2007;28:39-45
7. Ross RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009;30:156-163
8. Tóth A, Blumberg PM, Boczán J. Anandamide and the vanilloid receptor (TRPV1). Vitam Horm 2009;81:389-419
9. Di Marzo V, De Petrocellis L, Fezza F, et al. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 2002;66:377-391
10. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007;152:576-582
11. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90
12. Alexander SP, Kendall DA. The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 2007;152:602-623
13. Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 2009;89:112-119
14. Fowler CJ. The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 2006;20:549-562
15. Yates ML, Barker EL. Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Mol Pharmacol 2009;76:11-17
16. Simon GM, Cravatt BF. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 2008;283:9341-9349
17. Tsuboi K, Sun YX, Okamoto Y, et al. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 2005;280:11082-11092
18. Kaczocha M, Glaser ST, Chae J, et al. Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. J Biol Chem 2010;285:2796-2806
19. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007;14:1347-1356
20. Woodward DF, Carling RW, Cornell CL, et al. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther 2008;120:71-80
21. Pertwee RG. CB1 and CB2 receptor pharmacology. In: Kofalvi A, editor, Cannabinoids and the brain. Springer-Verlag, Heidelberg; 2008. p. 91-100
22. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7:438-455
23. Uhl GR, Ishiguro H, Onaivi ES, et al. Molecular neurobiological methods in marijuana--cannabinoid research. Methods Mol Med 2006;123:1-17
24. Kunos G, Bátkai S. Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice. Neurochem Res 2001;26:1015-1021
25. Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 2008;153:309-318
26. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res 2009;60:85-92
27. Randall MD. Endocannabinoids and the haematological system. Br J Pharmacol 2007;152:671-675
28. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007;18:27-37
29. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100
30. Guzmán M. Effects on cell viability. In: Pertwee RG, editor, Handbook of experimental pharmacology -- 168 -- cannabinoids. Springer-Verlag, Heidelberg; 2005. p. 627-642
31. Fernández-Ruiz J, González S, Romero J, Ramos JA. Cannabinoids in neurodegeneration and neuroprotection. In: Mechoulam R, editor, Cannabinoids as therapeutics (MDT). Birkhaüser Verlag, Basel; 2005. p. 79-109
32. Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 2007;28:180-187
33. Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007;36:68-74
34. Abrams DI, Guzmán M. Cannabinoids and cancer. In: Abrams DI, Weil A, editors, Integrative oncology. Oxford University Press, Oxford; 2008. p. 147-170
35. Sarfaraz S, Adhami VM, Syed DN, et al. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008;68:339-342
36. Irving AJ, McDonald NA, Harkany T. CB1 cannabinoid receptors: molecular biology, second messenger coupling and polarized trafficking in neurons. In: Kofalvi A, editor, Cannabinoids and the brain. Springer-Verlag, Heidelberg; 2008. p. 59-73
37. Prather PL. CB2 cannabinoid receptors: molecular, signaling and trafficking properties. In: Kofalvi A, editor, Cannabinoids and the brain. Springer-Verlag, Heidelberg; 2008. p. 75-90
38. Gerdeman GL, Fernández-Ruiz J. The endocannabinoid system in the physiology and pathophysiology of the basal ganglia. In: Kofalvi A, editor, Cannabinoids and the brain. Springer-Verlag, Heidelberg; 2008. p. 423-483
39. Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 2007;13:109-114
40. Hillard CJ. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des 2008;14:2347-2361
41. Hampson AJ, Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci 2001;13:1529-1536
42. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003;302:84-88
43. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998;54:459-462
44. Louw DF, Yang FW, Sutherland GR. The effect of D9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 2000;857:183-187
45. Nagayama T, Sinor AD, Simon RP, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999;19:2987-2995
46. Sinor AD, Irvin SM, Greenberg DA. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 2000;278:157-160
47. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001;413:527-531
48. Marsicano G, Moosmann B, Hermann H, et al. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002;80:448-456
49. de Lago E, Fernández-Ruiz J. Cannabinoids and neuroprotection in motor-related disorders. CNS Neurol Disord Drug Targets 2007;6:377-387
50. Bisogno T, Di Marzo V. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr Pharm Des 2008;14:2299-3305
51. Garc?́a-Arencibia M, Garc?́a C, Fernández-Ruiz J. Cannabinoids and Parkinson's disease. CNS Neurol Disord Drug Targets 2009;8:432-439
52. Pazos MR, Sagredo O, Fernández-Ruiz J. The endocannabinoid system in Huntington's disease. Curr Pharm Des 2008;14:2317-2325
53. Maccarrone M, Battista N, Centonze D. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog Neurobiol 2007;81:349-379
54. Bilsland LG, Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des 2008;14:2306-2316
55. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des 2008;14:2326-2336
56. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001;15:300-302
57. Witting A, Weydt P, Hong S, et al. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem 2004;89:1555-1557
58. van der Stelt M, Veldhuis WB, van Haaften GW, et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 2001;21:8765-8771
59. Hansen HH, Schmid PC, Bittigau P, et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 2001;78:1415-1427
60. Gubellini P, Picconi B, Bari M, et al. Experimental Parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 2002;22:6900-6907
61. Schabitz WR, Giuffrida A, Berger C, et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 2002;33:2112-2124
62. Jin KL, Mao XO, Goldsmith PC, Greenberg DA. CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 2000;48:257-261
63. Ashton JC, Rahman RM, Nair SM, et al. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 2007;412:114-117
64. Sagredo O, González S, Aroyo I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009;57:1154-1167
65. Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009;132:3152-3164
66. Benito C, Kim WK, Chavarria I, et al. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci 2005;25:2530-2536
67. Núñez E, Benito C, Tolón RM, et al. Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience 2008;151:104-110
68. Benito C, Nuñez E, Tolon RM, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003;23:11136-11141
69. Esposito G, Iuvone T, Savani C, et al. Opposing control of cannabinoid receptor stimulation on amyloid-beta induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther 2007;322:1144-1152
70. Zhang J, Hoffert C, Vu HK, et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003;17:2750-2754
71. Benito C, Romero JP, Tolon RM, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007;27:2396-2402
72. Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006;6:12
73. Maresz K, Carrier EJ, Ponomarev ED, et al. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005;95:437-445
74. Fernández-López D, Martínez-Orgado J, Nuñez E, et al. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 2006;60:169-173
75. Zhang M, Martin BR, Adler MW, et al. Cannabinoid CB2 receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 2007;27:1387-1396
76. Ramirez BG, Blazquez C, Gomez del Pulgar T, et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25:1904-1913
77. Kim K, Moore DH, Makriyannis A, Abood ME. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 2006;542:100-105
78. Arévalo-Martin A, Vela JM, Molina-Holgado E, et al. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003;23:2511-2516
79. Viscomi MT, Oddi S, Latini L, et al. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 2009;29:4564-4570
80. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 1996;93:3984-3989
81. Kim SR, Chung YC, Chung ES, et al. Roles of transient receptor potential vanilloid subType 1 and cannabinoid Type 1 receptors in the brain: neuroprotection versus neurotoxicity. Mol Neurobiol 2007;35:245-254
82. Abood ME, Rizvi G, Sallapudi N, McAllister SD. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 2001;309:197-201
83. van der Stelt M, Veldhuis WB, Bar PR, et al. Neuroprotection by D9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001;21:6475-6579
84. Parmentier-Batteur S, Jin K, Mao XO, et al. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002;22:9771-9775
85. Pintor A, Tebano MT, Martire A, et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006; 51:1004-1012
86. Raman C, McAllister SD, Rizvi G, et al. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:33-39
87. Lastres-Becker I, Bizat N, Boyer F, et al. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 2003;14:813-816
88. Hansen HH, Azcoitia I, Pons S, et al. Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem 2002;82:154-158
89. Muthian S, Rademacher DJ, Roelke CT, et al. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 2004;129:743-750
90. Berger C, Schmid PC, Schabitz WR, et al. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 2004;88:1159-1167
91. Sommer C, Schomacher M, Berger C, et al. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol 2006;112:277-286
92. Downer E, Boland B, Fogarty M, Campbell V. D9-tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurones via activation of the CB1 receptor. Neuroreport 2001;12:3973-3978
93. Schomacher M, Müller HD, Sommer C. Short-term ischemia usually used for ischemic preconditioning down-regulates central cannabinoid receptors in the gerbil hippocampus. Acta Neuropathol 2006;111:8-14
94. Pacher P, Haskó G. Endocannabinoids and cannabinoid receptors in ischaemia--reperfusion injury and preconditioning. Br J Pharmacol 2008;153:252-262
95. Shohami E, Mechoulam R. A non-psychotropic cannabinoid with neuroprotective properties. Drug Dev Res 2000;50:211-215
96. Hampson AJ, Bornheim LM, Scanziani M, et al. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 1998;70:671-676
97. Maas AI, Murray G, Henney H III, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006;5:38-45
98. De Petrocellis L, Di Marzo V. Role of endocannabinoids and endovanilloids in Ca2+ signalling. Cell Calcium 2009;45:611-624
99. Lozovaya N, Min R, Tsintsadze V, Burnashev N. Dual modulation of CNS voltage-gated calcium channels by cannabinoids: focus on CB1 receptor-independent effects. Cell Calcium 2009;46:154-162
100. Braida D, Pegorini S, Arcidiacono MV, et al. Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett 2003;346:61-64
101. Garc?́a-Arencibia M, González S, de Lago E, et al. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 2007;1134:162-170
102. Lastres-Becker I, Molina-Holgado F, Ramos JA, et al. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005;19:96-107
103. Iuvone T, Esposito G, Esposito R, et al. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004;89:134-141
104. Sagredo O, Ramos JA, Decio A, et al. Cannabidiol reduced the striatal atrophy caused by 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007;26:843-851
105. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)D 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998;95:8268-8273
106. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol--recent advances. Chem Biodivers 2007;4:1678-1692
107. Hayakawa K, Mishima K, Nozako M, et al. Repeated treatment with cannabidiol but not D9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 2007;52:1079-1087
108. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effects on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-852
109. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 2009;32:421-431
110. Sofroniew MV. Reactive astrocytes in neural repair and protection. Neuroscientist 2005;11:400-407
111. Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005;26:349-354
112. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology 2009;56:244-253
113. Massi P, Valenti M, Bolognini D, Parolaro D. Expression and function of the endocannabinoid system in glial cells. Curr Pharm Des 2008;14:2289-2298
114. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003;126:2191-2202
115. Palazuelos J, Davoust N, Julien B, et al. The CB2 cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008;283:13320-13329
116. Molina-Holgado F, Pinteaux E, Moore JD, et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003;23:6470-6474
117. Gómez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 2002;277:36527-36533
118. Molina-Holgado E, Vela JM, Arevalo-Martin A, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002;22:9742-9753
119. Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000;29:58-69
120. Mart?́nez-Orgado J, Fernández-López D, Lizasoain I, Romero J. The seek of neuroprotection: introducing cannabinoids. Recent Pat CNS Drug Discov 2007;2:131-139
121. Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 2007;5:73-80
122. Carrier EJ, Kearn CS, Barkmeier AJ, et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 2004;65:999-1007
123. Walter L, Franklin A, Witting A, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003;23:1398-1405
124. Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther 2002;95:191-202
125. Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 1998;76:824-836
126. Chen Y, McCarron RM, Ohara Y, et al. Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res 2000;87:323-327
127. Maccarrone M, Fiori A, Bari M, et al. Regulation by cannabinoid receptors of anandamide transport across the blood-- brain barrier and through other endothelial cells. Thromb Haemost 2006;95:117-127
128. Golech SA, McCarron RM, Chen Y, et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Mol Brain Res 2004;132:87-92